A New Drug For The Treatment Of Multiple Sclerosis.
An whizzo monitory panel of the US Food and Drug Administration on Thursday recommended that the operation approve an oral drug, Gilenia, as a first-line treatment for multiple sclerosis (MS). Gilenia appears to be both appropriate and effective, the panel confirmed in two separate votes.
Approval would end a major shift in MS therapy since other drugs for the neurodegenerative illness require frequent injections or intravenous infusions. "This is revolutionary," said Dr Janice Maldonado, an aide-de-camp professor of neurology at the University of Miami Miller School of Medicine. "It's a marvelous exploit of being the original oral drug out for relapsing multiple sclerosis".
Maldonado, who has participated in trials with the drug, said the results have been very encouraging. "All of our patients have done well and have not had any problems, so it's noticeably promising," she said. Patricia O'Looney, infirmity president of biomedical research at the National Multiple Sclerosis Society, went even further, saying that "this is a signal day. The panel recommended the approval of Gilenia as a first-line selection for people with MS".
